[1] He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network[J]. Nature, 2007, 447(7148): 1130-1134.
[2] Wang JX, Jiao JQ, Li Q, et al. MiR499 regulates mitochondrial dynamics by targeting calcineurin and dynaminrelated protein1[J]. Nat Med, 2011, 17(1): 71-78.
[3] Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and nonsmall cell lung cancer survival[J]. J Clin Invest, 2008, 118(7): 2600-2608.
[4] Stang A. Critical evaluation of the NewcastleOttawa scale for the assessment of the quality of nonrandomized studies in metaanalyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605.
[5] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses[J]. BMJ, 2003, 327(7414): 557-560.
[6] DerSimonian R, Kacker R. Randomeffects model for metaanalysis of clinical trials: an update[J]. Contemp Clin Trials, 2007, 28(2): 105-114.
[7] Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis[J]. Stat Med, 2002, 21(11): 1539-1558.
[8] Bensen JT, Tse CK, Nyante SJ, et al. Association of germline microRNA SNPs in premiRNA flanking region and breast cancer risk and survival: the carolina breast cancer study[J]. Cancer Causes Control, 2013, 24(6): 1099-1109.
[9] Gao LB, Li LJ, Pan XM, et al. A genetic variant in the promoter region of miR34b/c is associated with a reduced risk of colorectal cancer[J]. Biol Chem, 2013, 394(3): 415-420.
[10] Han Y, Pu R, Han X, et al. Associations of primiR34b/c and premiR196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk[J]. PLoS One, 2013, 8(3): e58564.
[11] Li L, Wu J, Sima X, et al. Interactions of miR34b/c and TP53 polymorphisms on the risk of nasopharyngeal carcinoma[J]. Tumour Biol, 2013, 34(3): 1919-1923.
[12] Oh J, Kim JW, Lee BE, et al. Polymorphisms of the primiR34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer[J]. Oncol Rep, 2014, 31(2): 995-1002.
[13] Son MS, Jang MJ, Jeon YJ, et al. Promoter polymorphisms of primiR34b/c are associated with hepatocellular carcinoma[J]. Gene, 2013, 524(2): 156-160.
[14] Xu Y, Liu L, Liu J, et al. A potentially functional polymorphism in the promoter region of miR34b/c is associated with all increased risk for primary hepatocellular carcinoma[J]. Int J Cancer, 2011, 128(2): 412-417.
[15] Yin J, Wang X, Zheng L, et al. HsamiR34b/c rs4938723 T>C and hsamiR423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population[J]. PLoS One, 2013, 8(11): e80570.
[16] Zhang S, Qian J, Cao Q, et al. A potentially functional polymorphism in the promoter region of miR34b/c is associated with renal cell cancer risk in a Chinese population[J]. Mutagenesis, 2014, 29(2): 149-154.
[17] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin4 encodes small RNAs with antisense complementarity to lin14[J]. Cell, 1993, 75(5): 843-854.
[18] Lee Y, Ahn C, Han J, et al. The nuclear RNase Ⅲ Drosha initiates microRNA processing[J]. Nature, 2003, 425(6956): 415-419.
[19] Kong W, Zhao JJ, He L, et al. Strategies for profiling microRNA expression[J]. J Cell Physiol, 2009, 218(1): 22-25.
[20] Hutvágner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNAinterference enzyme Dicer in the maturation of the let-7 small temporal RNA [J]. Science, 2001, 293(5531): 834-838.
[21] Dahiya N, ShermanBaust CA, Wang TL, et al. MicroRNA expression and identification of putative miRNA targets in ovatian cancer[J]. PLoS One, 2008, 3(6): e2436.
[22] Kogo R, Mimori K, Tanaka F, et al. Clinical significance of miR146a in gastric cancer cases[J]. Clin Cancer Res, 2011, 17(13): 4277-4284.
[23] Yu F, Yao H, Zhu P, et al. Let7 regulates self renewal and tumorigenicity of breast cancer cells[J]. Cell, 2007, 131(6): 1109-1123.
[24] Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis[J]. Nat Genet, 2007, 39(5): 673-677.
[25] Guo Z, Wu C, Wang X, et al. A polymorphism at the miR502 binding site in the 3′untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome[J]. Int J Cancer, 2012, 131(6):1318-1322.
[26] Liu AM, Zhang C, Burchard J, et al. Global regulation on microRNA in hepatitis B virusassociated hepatocellular carcinoma[J]. OMICS, 2011, 15(3): 187-191.
[27] 郭哲, 向邦德. 微小RNA在肝细胞癌及肝癌干细胞中的作用[J]. 国际肿瘤学杂志, 2011, 38(9): 680-683.
[28] 张灵敏, 王亚旭. 微小RNA与结直肠癌[J]. 国际肿瘤学杂志, 2014, 41(4):290-293. |